[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TNSN02037A1 - Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant - Google Patents

Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant

Info

Publication number
TNSN02037A1
TNSN02037A1 TNTNSN02037A TNSN02037A TNSN02037A1 TN SN02037 A1 TNSN02037 A1 TN SN02037A1 TN TNSN02037 A TNTNSN02037 A TN TNSN02037A TN SN02037 A TNSN02037 A TN SN02037A TN SN02037 A1 TNSN02037 A1 TN SN02037A1
Authority
TN
Tunisia
Prior art keywords
compositions containing
sulfonylpyridazinones
aldose reductase
containing same
novel inhibitors
Prior art date
Application number
TNTNSN02037A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN02037A1 publication Critical patent/TNSN02037A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE A, R1, R2, ET R3 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES COMPOSITIONS LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT DE DIVERSES MALADIES, NOTAMMENT DE COMPLICATIONS DU DIABETE ET D'UNE ISCHEMIE DU TISSU CARDIAQUE, ET EGALEMENT POUR CONFERER UNE CARDIO-PROTECTION.
TNTNSN02037A 2001-03-30 2002-03-29 Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant TNSN02037A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
TNSN02037A1 true TNSN02037A1 (fr) 2005-12-23

Family

ID=23071435

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN02037A TNSN02037A1 (fr) 2001-03-30 2002-03-29 Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant

Country Status (44)

Country Link
US (2) US6579879B2 (fr)
EP (3) EP1491541B1 (fr)
JP (1) JP2004528319A (fr)
KR (1) KR100586138B1 (fr)
CN (1) CN1215067C (fr)
AP (1) AP2002002461A0 (fr)
AR (1) AR035798A1 (fr)
AT (3) ATE352551T1 (fr)
AU (1) AU2002226634B2 (fr)
BG (1) BG108179A (fr)
BR (1) BR0208571A (fr)
CA (1) CA2442476A1 (fr)
CZ (1) CZ20032563A3 (fr)
DE (3) DE60202452C5 (fr)
DK (2) DK1491540T3 (fr)
EA (1) EA006023B1 (fr)
EC (1) ECSP034671A (fr)
EE (1) EE200300470A (fr)
ES (2) ES2274369T3 (fr)
GE (1) GEP20053675B (fr)
HK (1) HK1061678A1 (fr)
HR (1) HRP20030752A2 (fr)
HU (1) HUP0303644A3 (fr)
IL (1) IL156462A0 (fr)
IS (3) IS2205B (fr)
MA (1) MA27003A1 (fr)
MX (1) MXPA03008850A (fr)
MY (1) MY134304A (fr)
NO (1) NO20034345L (fr)
NZ (1) NZ528406A (fr)
OA (1) OA12453A (fr)
PA (1) PA8541801A1 (fr)
PE (1) PE20030007A1 (fr)
PL (1) PL365294A1 (fr)
PT (2) PT1491540E (fr)
SI (1) SI1373259T1 (fr)
SK (1) SK11852003A3 (fr)
TN (1) TNSN02037A1 (fr)
TW (1) TWI245762B (fr)
UA (1) UA73236C2 (fr)
UY (1) UY27237A1 (fr)
WO (1) WO2002079198A1 (fr)
YU (1) YU71403A (fr)
ZA (1) ZA200304671B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
DE60204611T2 (de) * 2001-02-28 2006-05-11 Pfizer Products Inc., Groton Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
AU2002226634B2 (en) * 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
BR0306730A (pt) 2002-01-09 2004-12-21 Pfizer Prod Inc Processo e intermediários para agentes antidiabéticos de piridazinona
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035251A1 (en) * 2004-06-30 2006-02-16 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP1973876A2 (fr) * 2006-01-13 2008-10-01 Wyeth 1h-indoles substitues par un groupe sulfonyle en tant que ligands pour les recepteurs de la 5-hydroxytryptamine
EP2431367A3 (fr) 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Composés cycliques condensés comme modulateurs du recepteur GPR40
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA2783699C (fr) 2009-12-08 2019-01-15 Case Western Reserve University Composes d'amines primaires destines au traitement de troubles oculaires
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
TWI464147B (zh) * 2011-09-15 2014-12-11 Univ Taipei Medical 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
US20180118756A1 (en) * 2015-04-14 2018-05-03 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
HUE064911T2 (hu) 2016-06-21 2024-04-28 Univ Columbia 4-oxo-3,4-dihidrotieno[3,4-d]piridazin vegyületek mint aldóz-reduktáz inhibitorok és felhasználási eljárásuk
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
WO2018058109A1 (fr) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions et méthodes pour le traitement de troubles métaboliques
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
CN118480009A (zh) 2017-02-06 2024-08-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7307059B2 (ja) 2017-07-28 2023-07-11 アプライド セラピューティクス， インコーポレイテッド ガラクトース血症を処置するための組成物および方法
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
EP3966320A4 (fr) 2019-05-07 2023-10-25 University of Miami Traitement et détection de neuropathies héréditaires et de troubles associés
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A2 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
WO2022120353A1 (fr) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
EP0516860A4 (en) * 1990-11-30 1993-12-01 Tsumura & Co. Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
BR9205810A (pt) 1991-03-28 1994-06-28 Pfizer Acidos piridazinona acéticos
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR20010015607A (ko) * 1997-09-24 2001-02-26 에사 헤이노넨, 마자 리타라 포스폴암밴 억제자로서 1-옥사, 아자 및티아나프탈렌-2-온의 비스에테르
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
AU2002226634B2 (en) * 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
EP1392310A1 (fr) * 2001-04-30 2004-03-03 Pfizer Products Inc. Combinaisons d'inhibiteurs d'aldose reductase et inhibiteurs de cyclo-oxygenase 2
BR0306730A (pt) * 2002-01-09 2004-12-21 Pfizer Prod Inc Processo e intermediários para agentes antidiabéticos de piridazinona

Also Published As

Publication number Publication date
EA006023B1 (ru) 2005-08-25
GEP20053675B (en) 2005-11-25
NO20034345D0 (no) 2003-09-29
MA27003A1 (fr) 2004-12-20
DK1491540T3 (da) 2007-03-26
AP2002002461A0 (en) 2002-06-30
DE60216823D1 (de) 2007-01-25
IS6845A (is) 2003-06-16
EA200300673A1 (ru) 2003-12-25
MXPA03008850A (es) 2003-12-04
CN1215067C (zh) 2005-08-17
US6579879B2 (en) 2003-06-17
TWI245762B (en) 2005-12-21
EP1491541B1 (fr) 2007-01-24
SI1373259T1 (en) 2005-04-30
IS8251A (is) 2006-01-23
ATE286049T1 (de) 2005-01-15
SK11852003A3 (sk) 2004-07-07
HRP20030752A2 (en) 2005-06-30
DK1373259T3 (da) 2005-03-29
IS8250A (is) 2006-01-23
EP1491540A1 (fr) 2004-12-29
KR20030088484A (ko) 2003-11-19
MY134304A (en) 2007-12-31
DE60202452D1 (de) 2005-02-03
NZ528406A (en) 2004-03-26
EP1373259B1 (fr) 2004-12-29
HK1061678A1 (en) 2004-09-30
ES2274369T3 (es) 2007-05-16
IL156462A0 (en) 2004-01-04
NO20034345L (no) 2003-09-29
CN1500087A (zh) 2004-05-26
ZA200304671B (en) 2004-06-25
ES2231681T3 (es) 2005-05-16
AU2002226634B2 (en) 2007-01-25
CA2442476A1 (fr) 2002-10-10
CZ20032563A3 (cs) 2004-05-12
DE60216823T2 (de) 2007-10-04
BG108179A (en) 2004-09-30
YU71403A (sh) 2006-05-25
PA8541801A1 (es) 2002-10-28
ECSP034671A (es) 2003-08-29
US20020143017A1 (en) 2002-10-03
IS2205B (is) 2007-02-15
ATE352551T1 (de) 2007-02-15
WO2002079198A1 (fr) 2002-10-10
EE200300470A (et) 2004-02-16
EP1491541A1 (fr) 2004-12-29
PL365294A1 (en) 2004-12-27
HUP0303644A2 (hu) 2004-03-01
DE60217930D1 (de) 2007-03-15
OA12453A (en) 2006-05-24
DE60202452C5 (de) 2006-11-23
PT1373259E (pt) 2005-03-31
PE20030007A1 (es) 2003-01-28
DE60202452T2 (de) 2006-02-09
US6849629B2 (en) 2005-02-01
UY27237A1 (es) 2002-12-31
DE60217930T2 (de) 2007-10-18
HUP0303644A3 (en) 2008-06-30
PT1491540E (pt) 2007-01-31
EP1491540B1 (fr) 2006-12-13
UA73236C2 (en) 2005-06-15
KR100586138B1 (ko) 2006-06-07
JP2004528319A (ja) 2004-09-16
ATE348100T1 (de) 2007-01-15
EP1373259A1 (fr) 2004-01-02
US20030162784A1 (en) 2003-08-28
BR0208571A (pt) 2004-03-23
AR035798A1 (es) 2004-07-14

Similar Documents

Publication Publication Date Title
TNSN02037A1 (fr) Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN01149A1 (fr) Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant.
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN01150A1 (fr) Pyrimidine-2,4,6- triones inhibitrices de metalloproteinases, et compositions les contenant.
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01019A1 (fr) Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN01095A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX ET COMPOSITIONS LES CONTENANT
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02022A1 (fr) Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00169A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
TNSN00239A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT